Daiichi Sankyo willfully infringed Seagen patent in creating Enhertu, court rules

A Texas federal court has determined that Daiichi Sankyo willfully infringed a Seagen patent in creating its breast cancer drug Enhertu. But it will not enhance a $41.8 million award resulting from a jury trial in April.